Tumors are marked by high levels of heterogeneity and out-of-control cell growth. They encompass an competing ecosystem, comprising a remarkable number of cancerous and unaffected cell sub-populations, including tumor-cell-related epithelial cells, infiltrated immune cells, fibroblasts, mesenchymal stroma/stem cells (MSCs), along with the surrounding endothelium of blood vessels (Fig. [1](#pby007F1){ref-type="fig"}).^[@pby007C1]^ At the cellular level, gradual tumor development and progression appears to follow a classical evolution-like process following a step-wise accumulation of selected genomic or epigenetic alterations, which in turn lead to positive selection and expansion of certain cell lineages while other cell populations are depleted (Fig. [2](#pby007F2){ref-type="fig"} and Fig. [3](#pby007F3){ref-type="fig"}).^[@pby007C2],[@pby007C3]^ This process, termed clonal evolution of tumors, or the stochastic model, is a dynamic process leading to continuous tumor remodeling with distinct dimensions of heterogeneity (Fig. [2](#pby007F2){ref-type="fig"}b).^[@pby007C2],[@pby007C4],[@pby007C5]^ Conversely, the cancer stem cell model (CSC model or hierarchical model) is the other main mechanism that drives cancer progression, with either single or multiple progenitors (Fig. [2](#pby007F2){ref-type="fig"}b). Interestingly, the heterogenetic patterns established with either the stochastic model or the CSC model are similar and hard to distinguish without identification, and in reality, they often co-occur. Indeed, CSCs usually are the cells that at a different lineage stage acquired mutations or epigenetic alternations that caused the cells to grow unchecked and form the tumor population at the clonal level.^[@pby007C6]^

![Interplay of key contributing factors to tumor heterogeneity. Both cell-intrinsic and cell-extrinsic factors contribute to tumor heterogeneity. Key cell-intrinsic factors include mutation, DNA-repair genes, epigenetic mechanisms, chromosome segregation and stability, as well as intracellular signaling. Non-genetic or phenotypic variations as a result of contributing cell-intrinsic factors are depicted by different cytoplasmic colors. Cell-extrinsic mechanisms affect and contribute to the unequal microenvironment, indirectly contributing to tumor heterogeneity. Multiple cell types and different inter- and intra-cell interactions within a tumor may exist (only representatives are shown here), hence selectively contributing to tumor heterogeneity.](pby007f01){#pby007F1}

![Contribution of tumor heterogeneity in cancer progression and metastasis. (a) Graphical representation of inter- and intra-tumor heterogeneity origins at macroscopic and microscopic levels. (b) Graphical summary of the two recognized heterogeneity models: clonal (stochastic) evolution and cancer stem cell (CSC), involving either monoclonal evolution or single progenitor, and polyclonal evolution or multiple progenitors, linking tumor cellular paths to different tumor heterogeneity. (c) Contributing role of tumor heterogeneity with respect to cancer progression and metastasis.](pby007f02){#pby007F2}

![Role of tumor heterogeneity in biomarker prediction and tumor resistance to clinical therapy. Initial cancer diagnosis and first treatment depends on initial cell and molecular characterization, derived from a small tumor fraction (biopsy, here figure shows a complete representation, but in some cases, it may be biased). In most cases, the current first-line treatments can successfully eliminate dominating cancer clones, with the cost of selecting resistant tumor clones through either differential sensitivity (1) or therapy-induced mutagenesis (2). These resistant clones are capable of driving disease progression and eventually metastasis. Hence, the clonal composition of metastatic lesions may significantly differ from clones in the primary tumor. As a result, initial treatment choice may not be effective in progressive metastatic disease. This necessitates a new diagnosis and additional comparative steps after relapse, prior to second and usually combined treatment options (i.e., immunotherapy, selective pathway component targeting and/or gene therapy) (Adapted from Tellez-Gabriel *et al.*, 2016; doi:10.3390/ijms17122142).](pby007f03){#pby007F3}

There are numerous recognized heterogeneity contributing and/or selection factors. For example, artificial intervention by chemotherapy or radiotherapy can positively act on the cancer evolution process by reshaping tumor cell populations at genomic, epigenomic, transcriptomic, and proteomic levels, ultimately leading to different phenotypic properties (Fig. [3](#pby007F3){ref-type="fig"}).^[@pby007C7]^ Furthermore, cancer cell interaction with the surrounding microenvironment, given the complexity within and outside the cancer cell, is known to contribute to tumor heterogeneity.^[@pby007C1]^

Based on numerous previous studies in multiple malignancies, tumor heterogeneity can be classified into inter-tumor (between tumors from different patients) or intra-tumor (within a single tumor, or tumor of a given patient) heterogeneity (Fig. [2](#pby007F2){ref-type="fig"}a), based on specific molecular biomarker patterns (Table [1](#pby007TB1){ref-type="table"}).^[@pby007C4],[@pby007C8]^ Inter- or intra-tumor heterogeneity marks a key challenge in oncology, with significant implications for selecting specific biomarkers and/or primary gene mutations to guide clinical decisions for precision cancer therapies.^[@pby007C2]^ The identification of alternatively expressed genes and multiple inter-/intra-cellular signaling pathways that drive phenotypic variation in multiple tumor types will also aid in the development of precise therapeutic approaches. Table 1.Identification of significant genomically altered genes from published TCGA data in 12 common cancer types.Cancer typeSample sizeSignificantly altered genesReferenceGlioblastoma206*TP53,ERBB2,NF1,PARK2,AKT3,FGFR2,IRS2,PTPRD,MLH1,MSH2,MSH6,PMS2,PIK3R1*doi:10.1038/nature07385Lung squamous cell carcinoma178*TP53,CDKN2A,PTEN,PIK3CA,MLL2,NOTCH1,RB1,HLA-A,NFE2L2,KEAP1*doi:10.1038/nature11404Lung adenocarcinoma230*TP53,NF1,RIT1,RBM10,ERBB2,MAP2K1,NRAS,HRAS,NKX2-1,TERT,MDM2,KRAS,EGFR,BRAF,PIK3CA,STK11,KEAP1,MET,CCNE1 CCND1, TERC,MECOM*doi:10.1038/nature13385Colon rectal cancer276*APC,TP53,KRAS,PIK3CA,FBXW7,SMAD4,TCF7L2,NRAS,CTNNB1 SMAD2,FAM123B,IGF2,NAV2,MYC,TGFBR2,BARF,MSH3,CASP8,CDC27,MAP7,PTEN,SOX9,ARID1A,FAM123B*doi:10.1038/nature11252Breast cancer510*PIK3CA,PTEN,AKT1,TP53,GATA3,CDH1,RB1,MLL3,MAP3K1,CDKN1B,TBX3,RUNX1,CBFB,AFF2,PIK3R1,PTPN22,PTPRD,NF1,SF3B1,CCND3*doi:10.1038/nature11412Ovarian carcinoma489*TP53,BRCA1,BRCA2,RB1,NF1,FAT3,CSMD3,GABRA6,CDK12,NOTCH,FOXM1,BRAF,PIK3CA,KRAS,NRAS,CCNE,MYC,ZMYND8,IRF2BP2,PAX8,TERT,ID4*doi:10.1038/nature10166Endometrial carcinoma373*PTEN,CTNNB1,PIK3CA,ARID1A,PPP2R1A,KRAS,MYC,ERBB2,CTNNB1,CCNE1,FGFR3,SOX17,TP53,PTEN,ARID5B,PIK3R1,FBXW7,POLE*doi:10.1038/nature12113Urothelial bladder carcinoma131*TP53,CDKN2A,FGFR3,PIK3CA,TSC1,RB1,HRAS,MLL2,CDKN1A,ERCC2,STAG2,RXRA,NFE2L2,ARID1A,KDM6A,EP300,FGFR3,PPARG E2F3, EGFR, CCND1,MDM2*doi:10.1038/nature12965Clear cell renal cell carcinoma446*VHL,PBRM1,BAP1,SETD2,HIF1A,PRKCI,MDS1,EVI1,MDM4,MYC,JAK2,CDKN2A,PTEN,NEGR1,QKI,CADM2,ARID1A,SMARCA4,PBAF*doi:10.1038/nature12222Gastric adenocarcinoma295*TP53,KRAS,ARID1A,PIK3CA,ERBB3,HLA-B,JAK2,PD-L1,PDCD1LG2,PTEN,SMAD4,CDKN2A,CDH1,RHOA*doi:10.1038/nature13480Head and neck cancer279*PIK3CA,TRAF3,E2F1,CDKN2A,HRAS,CASP8,NOTCH1,AJUBA,FAT1,NFE2L2,TP63,SOX2,EGFR,ERBB2,FGFR1*doi:10.1038/nature14129Cervical cancer228*APOBEC,SHKBP1,ERBB3,CASP8,HLA-A,TGFBR2,PD-L1,PDCD1LG2,BCAR4,KRAS,ARID1A,PTEN,PIK3CA,EP300,FBXW7,HLA-B,NFE2L2,MAPK1*doi:10.1038/nature21386

Genomic profiling technology, that is genome-wide next-generation sequencing (NGS), is increasingly used to uncover different aspects of genomic heterogeneity in many types of human diseases, including cancer.^[@pby007C9],[@pby007C10]^ The Cancer Genome Atlas (TCGA) project was a comprehensive and coordinated effort to accelerate our understanding of the molecular basis of multiple cancer types through application of genome-wide analysis technologies. The resulting data yielded insights into the close ties between tumor genetics and the evolutionary history of cellular processes across different cancer types.^[@pby007C11]^ In addition, the above-mentioned discoveries have significantly expanded our understanding of cancer at the molecular level. Evidence of this can be seen in the extensive application of NGS in cancer diagnosis and prognosis prediction in clinical settings, as well as a dramatic increase in the number of new drug discoveries that target specific biological pathways and/or genes that are studied in ongoing clinical trials. Furthermore, there has also been a significant acceleration in the use of NGS to create genomic signatures for use in precision medicine.^[@pby007C12],[@pby007C13]^

Highly promising and constantly refined single-cell sequencing (SCS) technologies offer an ultimate solution for tackling the previously encountered limitations of intra-tumor heterogeneity analysis.^[@pby007C5]^ Simply put, SCS involves two major steps: (i) single- or multiple omics profiling of a large number of single cells, and (ii) classifying each tumor into different sub-populations from multiple spatial regions within a tumor biopsy with the use of sophisticated bioinformatics tools. These steps allow prediction of potential molecular relationships among these sub-populations within a single tumor biopsy. Combined with the serial spatial sampling set from a given tumor, SCS allows tracing of existing tumor cell lineages, and elucidation of potential therapeutic failure and resistance mechanisms, to further reveal the intricacies of tumor evolution.^[@pby007C14],[@pby007C15]^ The aim of this review is to discuss the contribution of heterogeneity to cancer development and treatment, and to examine the potential implications and limitations of NGS in deciphering tumor biology, along with its clinical translation in precision medicine.

Articles associated with large-scale genomic studies and TCGA, reviews, and related new clinical trials for most common types of cancer published between January 1, 2012 and December 31, 2017 were collected using PubMed and accessible public databases. The cBioPortal web resource tool (<http://cbioportal.org>) was used for cancer genomic data evaluation, including somatic mutations, DNA copy-number alterations, mRNA and microRNA expression, DNA methylation, and protein and phosphoprotein abundance. This tool allows users to query genetic alterations for each gene and sample, as well as hypothesis testing concerning recurrence and genomic gene alteration events in various common cancers. [ClinicalTrials.gov](ClinicalTrials.gov) is the largest clinical trial database, currently holding registrations from more than 195 countries around the world, allowing insights into current ongoing clinical trials. Key word searches included genomics, heterogeneity, clinical features, drug resistance, clinical trials, and phase I-III. Further inclusion criteria for published genomic studies in this manuscript included: (i) a sample size of more than 120 patients for genomic studies, and (ii) at least 15 patient participants in clinical trials.

Cancer genomic heterogeneity associated with clinical features {#pby007s2}
==============================================================

Since the discovery by evolutionary biologist Julian Huxley in 1958, there have been remarkable advances in the knowledge of genomic diversity and single tumor heterogeneity.^[@pby007C2]^ Today, there are many recognized factors contributing to genetic instability, including mutation of DNA repair genes directly or indirectly responsible for chromosomal stability, exposure to environmental mutagens, epigenetic mechanisms, as well as defects in chromosomal segregation, ultimately driving carcinogenesis (Fig. [1](#pby007F1){ref-type="fig"}).^[@pby007C16],[@pby007C17]^ Another important issue to mention is that there are different types of genetic instability (i.e., deletion, amplification, point-mutations, etc.), which contribute to the high variability of cancer genomes, such as promoting genetic heterogeneity and ultimately differences in treatment response.^[@pby007C2],[@pby007C18],[@pby007C19]^

Identification of genomic heterogeneity in pan-cancer studies {#pby007s3}
=============================================================

Extensive cancer genome studies have established a comprehensive landscape of genomic and epigenetic heterogeneity, with a strong link to initiation and progression in major cancers.^[@pby007C16]^ Recent data obtained from inter- and intra-tumor comparisons (Fig. [1](#pby007F1){ref-type="fig"}a and b) link tumor heterogeneity to many types of malignant disease, that is lung,^[@pby007C20]^ breast,^[@pby007C21]^ prostate,^[@pby007C22]^ myeloma,^[@pby007C23]^ glioblastoma,^[@pby007C24]^ and colorectal cancers (CRCs),^[@pby007C25]^ as well as leukemia.^[@pby007C26]^ Molecular and phenotypic aberrant variations are not only common between tumors of different tissue and cell types, but also within a tumor derived from the same tissue or cell type within an individual patient.^[@pby007C12],[@pby007C16]^ For example, a study across 27 cancer types, including 3083 tumors and normal tissue pairs identified a total of 373 909 non-silent coding mutations by whole exome or whole genome sequencing.^[@pby007C27]^ A subsequent comparison revealed a 1000-fold difference between individual patient mutation rates within or across selected cancer types.^[@pby007C27]^ This evidence suggests that only a minority of these genes is essential for tumor development, with the majority having no significant biological impact (Table [1](#pby007TB1){ref-type="table"}).^[@pby007C27]^ Intriguingly, several recent studies highlighted remarkably divergent patterns of genetic alterations in primary tumors when compared with metastases obtained from the same patient, where the metastatic tumors had additional mutations that were not present in the primary tumor (Table [1](#pby007TB1){ref-type="table"}).^[@pby007C27]--[@pby007C29]^ Essentially, the scientists hypothesized that all cells within a tumor have an equal potential to maintain and advance the tumor to metastasis, pending the acquisition of the necessary capability (Fig. [2](#pby007F2){ref-type="fig"}c).^[@pby007C30]^ A TCGA study comprising 178 lung squamous cell carcinoma (LSCC) and normal pairs, identified a total of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy alteration within a given tumor.^[@pby007C20]^ Statistical analysis uncovered 18 commonly mutated genes in 178 LSCCs, with *TP53* being among them (Table [1](#pby007TB1){ref-type="table"}).^[@pby007C20]^ A very recent pan-cancer analysis, comprising over 3300 tumors, revealed a diverse genomic heterogeneity landscape across nine cancer types with a notable tendency for highly heterogeneous tumors to have lower levels of immune cell infiltration or T cell infiltration.^[@pby007C31]^ Cancers arise when a sufficient number of mutations have occurred in any given tumor cell pool.^[@pby007C32]^ These inevitably lead to accumulation of additional mutations within single cells that confer growth and survival advantages. Eventually, these cells will progressively give rise to new more aggressive progeny (Fig. [3](#pby007F3){ref-type="fig"}).^[@pby007C33],[@pby007C34]^ Furthermore, multiple studies also revealed that a single mutation in one gene (i.e., *KRASG12D*, *BRAFV600E*) could induce a quick and sufficient malignant transformation in corresponding tissues of several tumor types (Table [1](#pby007TB1){ref-type="table"}).^[@pby007C35],[@pby007C36]^ A significant association of high-level heterogeneity and poor survival was evident for lower grade glioma, prostate-, clear cell kidney carcinoma, head and neck-, as well as breast cancers, with borderline significance for melanoma.^[@pby007C18],[@pby007C31],[@pby007C37]^

Identification of genomic heterogeneity in hematological malignancy {#pby007s4}
===================================================================

The molecular pathogenesis of acute myeloid leukemia (AML) has been studied by applying cytogenetic analysis tools for more than three decades.^[@pby007C38]^ Characterization of AML genomes by next-generation sequencing has revealed that these tumors exhibit a relatively low recurrent somatic mutation rate, compared with most other cancers, with an average of only 13 identified mutations in AML associated genes (i.e., *DNMT3A*, *FLT3*, *NPM1*, *IDH1/2*, *RUNX1*, and *CEBPA*), along with recently discovered AML pathogenesis implicated genes (i.e., *U2AF1*, *EZH2*, *SMC1A*, and *SMC3*).^[@pby007C38]--[@pby007C40]^ These mutations mainly enhance proliferation and survival of hematopoietic progenitors through activation of signaling pathways (Fig. [4](#pby007F4){ref-type="fig"}).^[@pby007C39]^ A second class of mutated genes in AML includes transcription factors, such as *CEBPA* and *RUNX1*, which were found in \~20% of *de novo* normal cytogenetic AML, with short overall survival and relapse-free survival.^[@pby007C40]^ Mutations in *FLT3*, *NPM1*, and *CEBPA* have been shown to have a significant prognostic impact, which ultimately resulted in their inclusion within the risk stratification system of European Leukemia patients and their use in standard-of-care testing.^[@pby007C38],[@pby007C41]^*TP53* mutation is frequently associated with therapy-related myeloid neoplasm and adverse prognostic impact.^[@pby007C40]^ Somatic mutations in the epigenetic modifiers, *DNMT3A*, *IDH1/2*, and *TET2*, are considered initiating AML mutations.^[@pby007C42]^*NPM1* mutations confer a favorable prognosis only in the presence of a co-occurring *IDH1* or *IDH2* mutation. *IDH1* and *IDH2* inhibitors are currently being tested in clinical trials.^[@pby007C18]^

![Recurrent somatic alterations across common tumor types. Heatmap of significant genes that were genetically altered across the 18 most common cancers, as evaluated by the TCGA project. Percentage of alteration frequency (white = low to blue = high) for the genes is shown.](pby007f04){#pby007F4}

Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma in adults, accounting for 30-40% of newly diagnosed non-Hodgkin's lymphomas (NHL).^[@pby007C43]^ Historically, DLBCL has been divided into three molecular subtypes, including germinal center B cell-like (GBC), activated B cell-like (ABC), and the primary mediastinal B cell lymphoma (PMBL), with all exhibiting a striking heterogeneity in gene expression profiles as well as clinical outcomes.^[@pby007C44]^ Deep sequencing identified 322 genes that were recurrently mutated in DLBCLs, including *ARID1A*, *MEF2B*, *PIK3CD*, and *PIK3R1*, with additional genes involved in the *NF-kB* pathway (i.e., *TNFAIP3*) and *Wnt* pathway (i.e., *WIF1*).^[@pby007C45]^ The pathogenic driver status of *CARD11* alteration was reported by the discovery of gain of function germline mutations that drive constitutive *NF-kB* activation.^[@pby007C46]^ The GCB subtype was characterized by a more favorable outcome and a spectrum of genetic alterations, which include *PTEN* deletion and *EZH2* and *TP53* mutations.^[@pby007C43]^ The ABC subtype has a less favorable outcome, being associated with a distinct genetic background, and marked by translocations, *BCL2* amplification and *MYD88* mutation, which occur in approximately 30% of patients.^[@pby007C47]^ DLCBL patients with *MYD88* mutations are significantly older than patients without these mutations. PMBL displays an amplification of *JAK2* in 50% of cases and recurrent deletion of *SOCS1*, which is a suppressor of *JAK* signaling.^[@pby007C44]^ The relationship between therapy and genetic alteration is likely to contribute to convergent evolution, where mutation-conferring resistance will become highly prevalent in subsequently relapsed disease (Fig. [2](#pby007F2){ref-type="fig"}c). As aforementioned, the intensive application of high-throughput genomic analysis has enabled rapid progress in our understanding of genetic heterogeneity in hematologic malignancies. Altogether, these examples suggest that the promise of precision medicine is finally coming to fruition in the desired treatment of blood malignancies.

Identification of genomic heterogeneity in solid tumors {#pby007s5}
=======================================================

Lung cancer is the leading cause of solid cancer-related mortality worldwide.^[@pby007C20]^ The discovery of recurrent mutations in *EGFR* kinase and *ALK* genes has led to a remarkable change in lung cancer treatment.^[@pby007C48]^ Targeting mutations in *BRAF*, *AKT1*, *ERBB2*, and *PIK3CA* has achieved great success in cancer therapy.^[@pby007C48]^ Recently, the comprehensive TCGA study of lung cancer from three large cohorts of patients comprising NSCLC, adenocarcinoma (AD), and squamous cell carcinoma (SQCC) characterized the presence of complex genomic alterations in these cancers.^[@pby007C49]^ Differential activity of PI3K/AKT/mTOR and MAPK pathways was present across NSCLS genomic subtypes.^[@pby007C49]^ The activation of p38/MAPK and mTOR pathways within a subset of lung AD, compared with other subtypes of lung AD and SQCC, was conducted. Significant somatic copy number alterations for the following genes, *MDM2*, *KRAS*, *EGFR*, *MET*, *CCNE*, were found in lung AD, with gene amplifications strongly dominating (Table [1](#pby007TB1){ref-type="table"} and Fig. [4](#pby007F4){ref-type="fig"}). Interestingly, three AD associated subtypes expressed several immune checkpoint genes, commonly associated with tumor cells or gene products known to interact with T cells (i.e., *PD1*, *PDL1*, *PDL2*, *CD3*, and *CTL4*), and have been nominated as potential therapeutic targets. Gender in lung AD is significantly correlated with gene mutation patterns (*RBM10*) (Table [1](#pby007TB1){ref-type="table"}). The lung AD subtype appears to share similar gene patterns with many other cancer types, including CRC, stomach, pancreatic, breast, and liver cancers (Table [1](#pby007TB1){ref-type="table"}). As expected, lung SQCC cancers also share many alterations (i.e., *PIK3CA*, *PTEN*, *TP53*, *CDKN2A*, and *RAS*) with head and neck, bladder, as well as cervical cancers (Fig. [4](#pby007F4){ref-type="fig"}). A partial sharing with a multi-tissue squamous molecular subtype (Table [1](#pby007TB1){ref-type="table"} and Fig. [4](#pby007F4){ref-type="fig"}) is also evident, marked by high expression of both *SOX1* and *TP63* genes, providing further evidence of common dysfunction in cell cycle control. TCGA further revealed that *PIK3CA* is amplified or mutated in \~34% of HPV negative and 56% HPV positive head and neck squamous cell carcinoma (HNSCC) tumors (Table [1](#pby007TB1){ref-type="table"} and Fig. [4](#pby007F4){ref-type="fig"}), implicating the PI3K pathway in promoting growth factor dependent or independent growth, as well as the commonly observed EGFR therapy resistance.^[@pby007C50]^ It also promotes preferential expression of an oncogenic *ΔNP63* gene isoform of *TP63* encoded on chromosome 3 and involvement in squamous differentiation. Furthermore, a subset of \~22% of HPV positive HNSCC tumors had a notable 14q32.32 deletion or inactivating mutations in the *TNFR associated factor (TRAF3)* gene, with strong implications in suppressing survival of myeloid cancers and HPV positive HNSCC cell lines (Table [1](#pby007TB1){ref-type="table"}).^[@pby007C50]--[@pby007C52]^

Approximately 15% of CRC display a high level of microsatellite instability (MSI), caused by germline mutations in one or more DNA mismatch repair (MMR) genes, as well as somatic inactivation of the same pathway.^[@pby007C53]^ Patients with early stage MSI CRC tumors have a better prognosis, compared with those harboring microsatellite stable (MSS) tumors. It is widely recognized that multiple genetic pathways (i.e., *Wnt*, *RAS-MAPK*, *PI3K*, *TGF*, *TP53*, and DNA mismatch-repair) are altered between benign and malignant lesions in CRC.^[@pby007C54]^ As expected, the TCGA project identified 24 significantly mutated genes, including *APC*, *TP53*, *SMAD4*, *SOX9*, and *FAM123B* (Table [1](#pby007TB1){ref-type="table"} and Fig. [4](#pby007F4){ref-type="fig"}). Amplification of *ERBB2* and the newly discovered *IGF2* amplification was also observed, with promising drug-targetable potential. Mutated *APC*, *TP53*, *KRAS*, and *SMAD4* genes revealed a strong association with metastasis.^[@pby007C25]^ In early CRC stages, *SMAD4*, *TP53*, and *APC* appear to only display a very weak association with the disease outcome.^[@pby007C25]^*APC* is a tumor suppressor gene and its mutation is known to regulate growth advantage in epithelial cells, ultimately leading to small adenoma formation.^[@pby007C54]^ Subsequently, *KRAS* and *BRAF* mutations provide a second round of favorable cell expansion, resulting in large adenoma transformation.^[@pby007C25],[@pby007C55]^ Eventually, mutations in *PIK3CA*, *SMAD4*, and *TP53* genes generate a malignant tumor, with a high potential for invasion and metastasis.^[@pby007C25],[@pby007C54]^

Genomic analysis of the main breast cancer subtypes revealed that its cause was also associated with different subsets of molecular heterogeneity (Table [2](#pby007TB2){ref-type="table"}).^[@pby007C56]^ Clinically, this heterogeneity of breast cancer can be broadly categorized into three basic therapeutic groups: (i) the *estrogen receptor* (*ER*) positive group is the most numerous and diverse, with several genomic tests (*Ki-67*) to assist in predicting the outcome for *ER* positive patients receiving endocrine therapy^[@pby007C57]^; (ii) triple-negative breast cancer (*ER-, progesterone receptor* (*PR*)*- and human epidermal growth factor receptor-2* (*HER2*)) is an optimal patient group for chemotherapy options only, marked by increased incidence of germline *BRCA1* mutations^[@pby007C58]^; and (iii) basal-like breast cancer typically lacks expression of the molecular targets that confer responsiveness to highly effective targeted therapies, such as Tamoxifen and Aromatase inhibitors or Trastuzumab. The TCGA project revealed that somatic mutations in only three genes (i.e., *TP53*, *PIK3CA*, and *GATA3*) occurred at \>10% incidence across all breast cancer types (Table [2](#pby007TB2){ref-type="table"}).^[@pby007C56]^ Deletion or translocation events in tumor suppressor genes, such as *AKT3* and *MAG13*, lead to functional abnormalities and initiate breast tumorigenesis.^[@pby007C56]^ High levels of *APOBEC3B* gene expression have been shown to be associated with disease-free survival and overall survival outcomes in patients with *ER+* breast cancer.^[@pby007C59]^ Recent studies on breast cancer uncovered a list of driver genes, such as *CCND1*, *RB1*, *ERBB1*, *FGFR1*, *MYC*, and *PTEN* (Table [1](#pby007TB1){ref-type="table"} and Fig. [4](#pby007F4){ref-type="fig"}).^[@pby007C56]^ Variable frequencies of *HER2* gene amplification between primary tumors and their metastatic tumor or circulating tumor cells in advanced breast cancer have also been reported.^[@pby007C60],[@pby007C61]^ These studies suggest that a subset of patients with initial *HER2* negative primary tumors may develop *HER2* positive circulating tumor cells during disease progression, although the exact mechanism is still to be elucidated. Several studies also revealed a marked association between prior history of breast carcinoma and secondary acquired mutations in either primary or recurrent ovarian carcinomas, with breast carcinoma often preceding the ovarian carcinoma by many years.^[@pby007C62],[@pby007C63]^ Therefore, increased focus on driver mutations in tumorigenesis would provide critical insights for personalized therapeutics in cancer treatment. The identification of significant genomic heterogeneity from published TCGA project data derived from 12 cancer types is summarized in Table [1](#pby007TB1){ref-type="table"}. Table 2.Genomic heterogeneity in sub-types of breast-like cancer from the TCGA project.Mutated genesLuminal A (%)Luminal B (%)HER2(+) (%)Basal-like cancers (%)*PIK3CA*4529399*TP53*12297280*MAPK1*13540*MAP2K4*7220*AKT1*4220*PTEN*4421*RB1*0.40304

Association of cancer genetic heterogeneity and therapeutic failures {#pby007s6}
====================================================================

Genetic heterogeneity is a prominent contributor to therapeutic failure, with increased likelihood of resistance to future therapies. This generates a diverse cell population during tumor development and progression, representing a key determining factor for variation in tumor therapeutic response (Fig. [3](#pby007F3){ref-type="fig"}).^[@pby007C8],[@pby007C16]^ Resistance to single drug targeting therapies is frequent in cancer, and near universal in major metastatic carcinomas. *KRAS* mutations are known to confer resistance to *EGFR* targeting in cancer treatment.^[@pby007C64]^ The well-documented mechanisms of drug resistance to certain therapies are associated with alterations in signal transduction cascades, predominantly through activation of alternative or complementary pathways, often through molecular feedback loops.^[@pby007C65]^ Insights into the genomic landscape of some cancers, such as NSCLCs and breast cancers, have fueled a shift in the treatment paradigm towards the use of precise treatments.^[@pby007C49],[@pby007C66],[@pby007C67]^ Lung cancer patients with heterogeneous *EGFR* mutations appear to benefit less from the *EGFR* inhibitor Gefitinib than patients with homogeneous *EGFR* mutations.^[@pby007C68]^ Mutated *EGFR* was shown to be mediated by selected cells that harbor the *EGFR* gatekeeper mutation (T790M) and/or *MET* gene amplification.^[@pby007C69],[@pby007C70]^ The oncogenic *BRAF* amplification or *MEK1* mutation associated with resistance to *BRAF*-specific inhibitors in melanomas is also well documented.^[@pby007C71],[@pby007C72]^ However, *BRAF*^*V600E*^ mutations are among the most commonly reported molecular alterations in melanomas, and *BRAF* is currently a promising therapeutic target.^[@pby007C71]^ Successful clinical trials of selective BRAF inhibitors (i.e., 'Vemurafenib') in *BRAF*^*V600E*^ mutated versus non-mutated patient melanoma tumors support their substantial potential and clinical significance, together with patient-derived tumor genotyping, prior to appropriate treatment selection.^[@pby007C73]^ Chronic myeloid leukemia (CML) is a stem cell-like disease, marked by the presence of rare cell clones in about half of patients with unique *BCR-ABL* resistant mutations, possibly acquired after Imatinib treatment.^[@pby007C74]^ Furthermore, impairment of apoptotic cell death plays a major role in therapy resistance and relapse in acute lymphoblastic leukemia (ALL).^[@pby007C75]^ Recent studies have shown that apoptosis *protein inhibitor interacting protein kinase 1 (RIP1)* inhibitor 'Birinapant' potently induced cell death in patient-derived ALL cells both *in vitro* and *in vivo*.^[@pby007C76],[@pby007C77]^ Patients in leukemic relapse are notoriously difficult to treat because drug resistance of leukemic clones is an insurmountable obstacle to effective chemotherapy in AML.^[@pby007C78]^ Loss of tumor suppressor *BRCA1/2* gene heterozygosity highly sensitizes patients to DNA cross-linking agents (platinum drugs) in ovarian or breast cancer.^[@pby007C79]^ Predictive capability of platinum resistance through the presence of secondary *BRCA1/2* mutations in ovarian cancer has been documented in *in vitro* and *in vivo* studies.^[@pby007C63]^ CRC resistance to targeted therapy noted during disease progression is often occurring within 3-12 months after *EGRF* antagonist administration, demanding a change in the treatment choice.^[@pby007C80]^ Proposed mechanisms associated with the failure of improved outcomes in CRC patients were linked to microscopic residual disease and the absence of tumor neoangiogenesis after 'Bevacizumab' (anti-*EGFR* antibody) application, as well as the epithelial to mesenchyme transition phenotype after 'Cetuximab' (anti-EGFR antibody) treatment.^[@pby007C81]^ Furthermore, the expression of the *excision repair cross-complementation group 1 (ERCC1)* gene is under increased investigation as a potential resistance predictive marker to platinum compounds in CRC.^[@pby007C82]^ The benefit of chemotherapy is further increased with combined targeting therapies (i.e., 'Bevacizumab,' 'Cetuximab,' or 'Panitumumab') in CRC patients with *RAS*-wild type harboring tumors.^[@pby007C83]^ In addition, preliminary clinical data have revealed that *HER2* is amplified in around 5% of patients with *KRAS*-wild type metastatic CRC, suggesting that this patient subset may benefit from dual *HER2* inhibitors (i.e., 'Trastuzuman' and 'Lapatinib').^[@pby007C84]^

Drug resistance mechanisms of selected tumor clones and the extremely intra-heterogeneous nature of the tumor are also widely accepted (Fig. [3](#pby007F3){ref-type="fig"}).^[@pby007C85]^ This leads to significant practical difficulties in identifying the most aggressive or drug resistant clones to deliver targeted therapy, through well-established conventional bulk sequencing approaches.^[@pby007C11]^ At present, targeted therapeutic reagents are dependent upon biomarkers that are derived from primary tumor biopsies that are subjected to genomic sequencing. However, dramatic responses to initial therapy and relapse typically take place within 1-2 years following treatment initiation, which commonly arise from selective pressures created by the dynamic nature of the targeting agent.^[@pby007C86]^ Furthermore, drug response failure of sub-clones within certain cancer tissues substantially limits the ability to predict treatment response.^[@pby007C87]^ Our current understanding of heterogeneity extent in cancers is largely derived from bulk tumor specimen analysis. It should be noted that most bulk tumor samples are a mixture of non-malignant cells and diverse cancer cell sub-populations (Fig. [2](#pby007F2){ref-type="fig"} and Fig. [3](#pby007F3){ref-type="fig"}). The implementation of single-cell analysis (SCA) technologies to study cancer heterogeneity has shown a strong potential to reveal genome-wide molecular profiles, regulation, and mechanisms, with unprecedented resolution.^[@pby007C5],[@pby007C88]^ This state-of-the-art methodology allows, with reliable precision, the isolation and characterization of individual cells among a heterogeneous cell mixture. It further grants an opportunity for future breakthroughs in understanding the dynamic genetic heterogeneity in tumors, along with cancer origin, progression, and clinical management.

Advances of SCA technology to uncover dynamic genetic heterogeneity {#pby007s7}
===================================================================

Over the past few years, technological advances at the single-cell level have made high-throughput sequencing of tumor genomes possible. An increasing number of reported single-cell studies demonstrate considerable cell-to-cell variability in apparently homogeneous populations. Application of SCA has greatly enhanced the power of systematic cancer heterogeneity characterization, resulting in significant mechanistic insights into tumor progression.

Single-cell gene expression analysis dates back to the early 1990s^[@pby007C89]^; however, it is in the last decade that a significant advance has been achieved in SCA technology development (refer to reviews^[@pby007C14],[@pby007C90]^). To date, it is becoming possible to assay a substantial number (\>100) of secreted proteins, cell surface markers, signaling pathway components, and even metabolites at the single-cell level.^[@pby007C90]^ The most significant progress of SCA tool development is evident at the genomic, transcriptomic, epigenetic, and proteomic levels.^[@pby007C5],[@pby007C90]^ SCA tools significantly contributed to the identification and characterization of cancer stem cells. The success of scRNA-seq in this area was marked by the discovery of 'stemness'-like cells by analyzing transcriptome- and gene expression signatures of *in vivo* differentiated glioblastoma cells,^[@pby007C91]^ as well as metastatic breast tumors.^[@pby007C92]^ These observations support the theory that initial tumor stem cells may initiate and propagate metastatic cancer behavior.

As an application with a great clinical potential, SCA was applied to circulating tumor cells (CTCs). The previously impossible detection and characterization of CTCs, originating from tumors and at 1:10^9^ ratio in the bloodstream, has been made possible through SCA techniques.^[@pby007C92]^ The previously unreliable method of using magnetic beads coupled to a cell surface ECAM (Epithelial Cell Adhesion Molecule) recognizing antibody, has been optimized for single-cell CTC isolation from whole blood, by considering factors such as microscopic imaging, cell size, and passive capture.^[@pby007C93],[@pby007C94]^ The elucidation of cancer progression through the comparison of genomic and transcriptomic derived CTC profiles has also been reported.^[@pby007C95],[@pby007C96]^

By using single-cell adapted whole-genome sequencing, the discovery of the metastatic pathway (potentially because of differential CNV patterns) from lung cancer-derived CTCs was achieved.^[@pby007C97],[@pby007C96]^ The promising applications of non-invasive SCAs to study cancer development, as well as cancer therapy resistance following chemotherapy are also evident.^[@pby007C98]^ Currently, two prevalent therapy resistance theories exist: (i) adaptive resistance, where low frequency mutations in the original population are selected for and eventually rise in frequency during chemotherapy; or (ii) acquired resistance, where resistance-conferring mutations are directly linked to chemotherapy.^[@pby007C90]^ As a consequence, the main goal and use of SCAs in clinical settings has been detection and evaluation of mutational differences over time in CTCs (i.e., before and after treatment). Eventually, this will lead to insights into the mechanisms of therapeutic resistance development in various cancer types, with subsequent validation of the aforementioned resistance theories. The use of SCA technology to study the response of mutated *BRAF*^*V600E*^ melanoma to RAF- or RAF/MEK combined inhibitors *in vitro* or *in vivo* led to the discovery of an overexpressed, and well-known *AXL* resistance marker, which was also linked to the adaptive resistance mechanism.^[@pby007C90],[@pby007C99]^ In another study, CTC tracking and subsequent whole-genome sequencing of prostate-derived cells, before or after androgen (AR)-targeted therapy, led to the discovery of two distinct resistant and AR amplified cell populations.^[@pby007C100]^ One of the populations was shown to be closely related to the cells prior to initiated therapy, supporting the adaptive resistance theory.^[@pby007C100]^ Furthermore, identification of heterogeneous resistance-conferring changes in the AR-independent Wnt signaling pathway could be derived using the scRNA-seq technique.^[@pby007C101]^ In addition, following 'Trastuzumab' treatment of *HER2* mutated breast tumor samples and subsequent STAR-FISH SCA, a close link between increased *PIK3CA* mutations and increased dispersion, as well as decreased frequency of *HER2* amplification and chemotherapeutic resistance, was detected.^[@pby007C102]^ The authors concluded that 'Trastuzumab' treatment has no benefit to patients who had already received chemotherapy and that the STAR-FISH approach could be used to predict poor prognosis.^[@pby007C102]^

Clinical studies elucidating potential therapeutic significance of genetic heterogeneity for precision medicine {#pby007s8}
===============================================================================================================

The subsequently mentioned studies further clarify the concept of tumor heterogeneity and its related pathogenesis, presenting a major area for new therapeutic approaches. Major subsets of molecular alterations in key pathways and driver mutations have interesting potential for targeting PI3K, mTOR, ERK/MAPK pathways, as well as checkpoint immunotherapy.

PI3K-AKT-mTOR inhibitors {#pby007s9}
========================

The PI3K-AKT-mTOR pathway plays a critical role for many cellular functions, such as growth control, survival, and metabolism, and is known to be highly activated in human cancers.^[@pby007C103]^ Previous studies have shown that PI3K-AKT-mTOR pathway over-activation is associated with mutations and amplification of genes encoding receptor tyrosine kinases (i.e., *HER2* or *EGFR*), *PIK3CA* mutations, *PTEN* loss and/or mutation, and *KRAS* mutations during carcinogenesis (Table [1](#pby007TB1){ref-type="table"} and Fig. [4](#pby007F4){ref-type="fig"}). A significant amount of effort has been put into development of drugs targeting several kinases throughout the phosphatidylinositol-3-kinase (PI3K) pathway for cancer therapy. Novel PI3K target inhibitors are currently being investigated in phase II and phase III clinical trials for various cancers (Table [3](#pby007TB3){ref-type="table"}). There are different isoforms of PI3Ks, such as PI3K-α, β, γ, and δ, with studied inhibitors known to inhibit one or more isoforms.^[@pby007C104]^ 'Idelalisib' (GS-1101 or CAL-101), a selective PI3K-δ inhibitor was approved in 2014 by the US FDA for treatment of various hematological malignancies, including chronic lymphocytic leukemia (CLL), relapsed B-cell non-Hodgkin's lymphoma, and relapsed small lymphocytic lymphoma.^[@pby007C105]^ 'Copanlisib' (BAY 80-6946), a PI3K inhibitor predominantly targeting PI3K-α and PI3K-γ isoforms was the second FDA-approved drug in 2017 to treat adult patients with relapsed lymphoma.^[@pby007C106]^ The BMK120 and BYL719 compounds are pan-PI3K inhibitors that have demonstrated preliminary selective activity in preclinical models of solid tumors.^[@pby007C104]^ Both compounds have shown favorable tolerability profiles with consistent on-target inhibition of PI3K. They have been studied as therapeutic targets either alone or in combination in phase II trials against solid tumors and hematologic malignancies (Table [3](#pby007TB3){ref-type="table"}). PI3K-AKT-mTOR is the most frequently activated signaling pathway in breast cancer.^[@pby007C56]^ 'Everolimus' (RAD-001), a selective inhibitor against mammalian target of rapamycin (mTOR), has been investigated in a phase III clinical trial and in combination with 'Exemestane' trials (funded by Novartis, NCT00863655) for ER positive advanced breast cancer.^[@pby007C66]^ The results have shown that the median progression-free survival was 6.9 months with 'everolimus' plus 'Exemestane' and 2.8 months with placebo plus 'Exemestane'.^[@pby007C66]^ 'Buparlisib' (BKM120) is an oral pyrimidine-derived reversible pan-PI3K inhibitor with specific and potent activity against mutant PI3K-α, as well as wild-type PI3K-α, β, γ, and δ isoforms, but no inhibitory activity against the class III PI3K or mammalian target of Rapamycin (mTOR). A phase IB/II study has investigated combined 'Buparlisib' and 'Trastuzumab' (NCT01132664) treatment in relapsed HER2 (+) breast cancer that previously failed with 'Trastuzumab' alone (Table [3](#pby007TB3){ref-type="table"}).^[@pby007C107],[@pby007C108]^ The data revealed that 'Buparlisib' and 'Trastuzumab' were well tolerated, with preliminary signs of clinical activity being observed in two partial responders and seven patients with stable disease. This promising outcome has led to further ongoing investigations of PI3K inhibitors in patients with HER2 (+), HER2 (-), and/or AR (+) triple negative metastatic breast cancer (NCT01816594, NCT02379247, NCT02457910) (refer to Table [3](#pby007TB3){ref-type="table"}). PI3K-AKT-mTOR pathway alterations associated with *PIK3CA* mutation are evident in almost a third of HNSCC (Table [1](#pby007TB1){ref-type="table"} and Fig. [4](#pby007F4){ref-type="fig"}). A number of first generation PI3K and mTOR inhibitors (i.e., 'Rapamycin', 'Temsorlimus' (CCI-779), 'Everolimus' (RAD-001)) have shown activity in *in vivo* preclinical models.^[@pby007C109]^ 'Alpelisib' (BYL719), specifically inhibits PIK3 in the PI3K/AKT kinase signaling pathway. 'Alpelisib' in combination with 'Cetuximab' have demonstrated synergistic activity in HNSCC cell lines, resulting in induced tumor regression in *PIK3CA* mutant HNSCC xenograft model.^[@pby007C109]^ Currently, two ongoing phase II clinical trials are assessing 'Buparlisib' (BKM120) in recurrent or metastatic HNSCC on 'Cisplatin'- and 'Cetuximab'-based chemotherapy in *PIK3CA*-mutated and wild-type patient cohorts (NCT01737450, NCT01816984, refer to Table [3](#pby007TB3){ref-type="table"}). Loss of *PTEN* is associated with increased PI3K-AKT pathway activation and is commonly observed in up to 30% of melanomas, and frequently also observed in tumors with a concurrent activating BRAF mutation (Table [1](#pby007TB1){ref-type="table"} and Fig. [4](#pby007F4){ref-type="fig"}). A phase I/II clinical trial of GSK2636771 in combination with 'pembrolizumab' is currently ongoing in patients with refractory (non-responsive to treatment) metastatic melanoma (NCT03131908, refer to Table [3](#pby007TB3){ref-type="table"}). A summary of previous and ongoing clinical trials of individual, as well as combined PI3K, mTOR and AKT inhibitors (as registered in [ClinicalTrials.gov](ClinicalTrials.gov)) is provided in Table [3](#pby007TB3){ref-type="table"}. Table 3.Summary of small molecule inhibitor clinical trials in human cancers. Data taken from <http://clinicaltrials.gov/>.DrugCombinationSponsorTumor typeSample sizeStatusRecruitment StatusClinical trial ID**PI3K inhibitors** BAY80-6946  (Copanlisib)-BayerLymphoma, Non-Hodgkin's227Phase IIActiveNCT01660451 BKM120-Hospices Civils de LyonThyroid Cancers47Phase IIActiveNCT01830504 BKM120-SOLTI Breast Cancer Research GroupTriple Negative Metastatic Breast Cancer50Phase IICompletedNCT01629615 BKM120Centre Leon BerardMetastatic Head and Neck Cancer Recurrent or Progressive70Phase IIRecruitingNCT01737450 BKM120CetuximabUniversity of ChicagoRecurrent or Metastatic Head and Neck Cancer30Phase IIActiveNCT01816984 PQR309-PIQUR Therapeutics AGLymphoma, Malignant72Phase IIRecruitingNCT02249429-Endometrial Clear Cell Adenocarcinoma-Endometrial Adenosquamous Carcinoma BKM120TrastuzumabNovartis PharmaceuticalsHER2-positive Primary Breast Cancer50Phase I/IICompletedNCT01816594 BYL719PaclitaxelPriyanka SharmaHER-2 Negative Breast Cancer44Phase I/IIActiveNCT02379247 TaselisibEnzalutamideVanderbilt-Ingram Cancer CenterAR Positive Triple-Negative Metastatic Breast Cancer73Phase I/IIRecruitingNCT02457910 IdelalisibEntospletinibHematologic Malignancies66Phase I/IICompletedNCT01796470 GSK2636771PembrolizumabM.D. Anderson Cancer CenterMetastatic Melanoma and PTEN Loss41Phase I/IIRecruitingNCT03131908 EverolimusExemestaneNovartis PharmaceuticalsMetastatic Breast Cancer with ER+Phase IIICompletedNCT00863655**Akt inhibitors** Akt Inhibitor MK2206-National Cancer Institute (NCI)Endometrial Adenocarcinoma37Phase IICompletedNCT01307631 Akt Inhibitor MK2206-National Cancer Institute (NCI)CRC18Phase IICompletedNCT01802320 MK-2206 + AZD6244-National Cancer Institute (NCI)Colorectal Neoplasms21Phase IICompletedNCT01333475**mTOR inhibitors** EverolimusVinorebineAIO-Studien-gGmbHAdvanced Breast Cancer139Phase IICompletedNCT01520103 BEZ235-Novartis PharmaceuticalsPancreatic Neuroendocrine Tumors (pNET)31Phase IICompletedNCT01658436 Rapamycin-The University of Texas Health Science Center at San AntonioCancer of Breast60Phase IIRecruitingNCT02642094 Everolimus-M.D. Anderson Cancer CenterEndometrial Cancer270Phase IIRecruitingNCT02397083 Everolimus-University of Texas Southwestern Medical CenterChildren With Recurrent or Progressive Ependymoma18Phase IIRecruitingNCT02155920 Everolimus-National Cancer Institute (NCI)Kidney Cancer or Renal Cancer18Phase IIRecruitingNCT02504892 TAK-228-Fox Chase Cancer CenterSoft Tissue Sarcomas33Phase IIRecruitingNCT02987959 AZD2014-Canadian Cancer Trials GroupGlioblastoma Multiforme52Phase IIRecruitingNCT02619864 EverolimusCisplatinJenny C. Chang, MDTriple Negative Breast Cancer32Phase I/IIRecruitingNCT01931163 EverolimusSorafenib TosylateAlliance for Clinical Trials in OncologyThyroid Cancer34Phase I/IIRecruitingNCT02143726 EverolimusLEE011Memorial Sloan Kettering Cancer CenterNeuroendocrine Tumors41Phase I/IIRecruitingNCT03070301 Sirolimus+CisplatinUniversity of WashingtonBladder Cancer21Phase I/IICompletedNCT01938573 EnzalutamideLY3023414Eli Lilly and CompanyProstate Cancer144Phase I/IIRecruitingNCT02407054**ERK1/2 and MAPK inhibitors** Regorafenib-Gerald BatistMetastatic Colorectal Cancer52Phase IIRecruitingNCT01949194 Vandetanib-Ronald WeigelInvasive Breast Cancer100Phase IIRecruitingNCT01934335 BVD-523-BioMed Valley Discoveries, IncMyelodysplastic Syndrome53Phase IICompletedNCT02296242 TDM1Abraxane, LapatinibJenny C. Chang, MDMetastatic HER2 Positive Breast Cancer45Phase I/IIRecruitingNCT02073916 LY2228820Radiotherapy + TMZCentre Jean PerrinNewly Diagnosed Glioblastoma50Phase I/IIRecruitingNCT02364206 DabrafenibPazopanib hydrochlorideManisha ShahUnspecified Adult Solid Tumor56Phase 1Active, not recruitingNCT01713972 GSK2118436GSK1120212Novartis PharmaceuticalsCancer430Phase 2Active, not recruitingNCT01072175**NFκB inhibitors** Pentoxifylline-Ramón Óscar González-Ramella, Ph.DPediatric Acute Lymphoblastic Leukemia44Phase IIRecruitingNCT02451774 Dexamethasone-Emory UniversityPlasma Cell Myeloma90Phase IIRecruitingNCT02765854 Ibrutinib-Icahn School of Medicine at Mount SinaiMultiple Myeloma Patients36Phase IIRecruitingNCT02943473 Lansoprazole-National Health Research Institutes, TaiwanEarly-stage HP(+) Gastric Pure DLBCL30Phase IIRecruitingNCT02388581 IbrutinibRituximabSamsung Medical CenterEB+ Diffuse Large B-cell Lymphoma24Phase I/IIRecruitingNCT02670616

MARK/MEK inhibitors {#pby007s10}
===================

The mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) signaling cascade is tightly regulated by phosphatases and bi-directional communication with other pathways, such as the AKT/mTOR pathway.^[@pby007C110]^ This pathway is vital for human cancer cell survival, dissemination, and drug resistance development. It is known to be frequently activated by a wide variety of receptors, including upstream genomic events and/or activation of multiple signaling events in solid and hematological malignancies.^[@pby007C103]^ Genomic tumor profiling has identified amplifications of several growth factor receptor genes, including *EGFR*, *ERBB2*, *IGF1R*, *FGFR1*, and mutations in *RAS*, *BRAF* and *MAPK/ERK* pathway genes that are ready for targeting in cancer treatment (Table [1](#pby007TB1){ref-type="table"}, Table [3](#pby007TB3){ref-type="table"}, and Fig. [4](#pby007F4){ref-type="fig"}). Currently approved B-RAF kinase inhibitors (BRAFi) for melanoma treatment are being investigated either alone or in combination with other agents in many other tumor types (refer to Table [3](#pby007TB3){ref-type="table"}). The clinical trial using CDK inhibitor 'LEE011' in combination with phase II BRAF inhibitor 'Encorafenib' (LGX818), with the aim to target key enzymes in the MAPK signaling pathway of *BRAF* mutant melanoma patients, was abandoned because of safety concerns (NCT01777776, refer to Table [3](#pby007TB3){ref-type="table"}).^[@pby007C111]^ However, therapies targeting MAPK/ERK components appear to have variable responses, when used in different solid tumors, including breast cancer, CRC, and glioblastoma (Table [3](#pby007TB3){ref-type="table"}). BRAF and MEK inhibition results in increased melanoma antigen expression, as observed in melanoma cell lines.^[@pby007C110]^ This phenomenon may increase tumor recognition by T-cells, with a strong potential to develop into a successful immunotherapeutic approach, warranting further exploration into combined approaches of immunotherapies and MAPK/ERK inhibitors.^[@pby007C112]^ Currently ongoing Phase II clinical trials using agents targeting BRAF and MEK kinases are summarized in Table [3](#pby007TB3){ref-type="table"}.

Nuclear factor kappa-B (NF-κB) inhibitors {#pby007s11}
=========================================

The implication of the NF-κB signaling pathway has been well established in recent decades in both physiologic and pathologic conditions, including cancer.^[@pby007C113]^ The role of NF-κB in human cancer initiation, metastasis, and resistance to treatment has been exclusively investigated and has drawn particular attention. A significant number of human cancer genomic studies have revealed that NK-κB activation is highly associated with an inflammatory microenvironment and various oncogenic mutations.^[@pby007C114]^ It appears to be a key mediator in the crosstalk between inflammation and carcinogenesis. The NK-κB family consists of five master transcription factors, including NF-κB1, NF-κB2, RelA, RelB, and c-Rel, which bind to DNA and regulate gene transcription. The role of NF-κB in cancer development started to be closely investigated when several NF-kB family genes were found to harbor rare mutations in certain types of cancers, especially in hematopoietic malignancies.^[@pby007C114]^ As such, a large cohort study in DLBCL was characterized by preferential activation of the NF-κB pathway and subsequent nuclear expression of p50/p65 and p50/c-Rel dimers, compared with germinal B cell lymphocytes.^[@pby007C115]^ Amplifications and rearrangements in *c-Rel* genes are often detected in various non-Hodgkin's B cell lymphomas.^[@pby007C116]^ NF-κB also plays a significant role in metastasis of several solid tumors, including breast cancer, HNSCC, and lung cancer.^[@pby007C113]^ It has been shown that inhibition of NF-κB abolishes VEGF production and subsequent angiogenesis in a variety of conditions.^[@pby007C117]^ In addition, NF-κB induces the expression of anti-apoptotic genes, such as caspase-8 inhibitor FLIP, inhibitor of apoptosis genes *c-IAP1/2* and *XIAP*, as well as apoptosis regulating genes belonging to the Bcl-2 family. Furthermore, many oncogenic mutations in *EGFR*, *Ras*, *PI3K*, and *TP53* genes are known to contribute to NF-κB activation in cells derived from pancreatic, colorectal, and lung tumors, further warranting NF-kB targeting as a cancer therapy.^[@pby007C117],[@pby007C118]^ Recently, therapeutic agents specifically targeting the NF-kB pathway have been considered to be front-line therapy. 'Pentoxifylline' specifically targets c-Rel nuclear translocation and also inhibits NFAT, which is currently under investigation in a phase II clinical trial involving pediatric ALL patients (NCT02451774, refer to Table [2](#pby007TB2){ref-type="table"}). 'Ibrutinib' selectively inhibits BCR and NF-kB singling, hence reducing cell proliferation in CLL patients that is characterized by prominent activation of NF-kB and BCR.^[@pby007C43],[@pby007C74]^ The phase I/II clinical trial applying 'Ibrutinib' either alone or in combination with EGFR inhibitor 'Rituximab' is being currently tested in DLBCL patients (NCT02670616, NCT02388581, refer to Table [3](#pby007TB3){ref-type="table"}). Hundreds of natural and synthetic compounds have been reported to selectively inhibit NF-kB; however, their clinical application has shown little efficacy, except for certain types of lymphoma and leukemia.^[@pby007C119]^ There is evidence that various NF-kB inhibitors prolonged survival in NSCLC mouse tumor models, induced by *KRAS* and *TP53* compound mutations; however, resistant tumors appeared within several weeks.^[@pby007C120]^ Mechanisms that led to this resistance remain unclear. Nevertheless, NF-κB inhibitors still appear attractive, although combinations with other chemotherapies are currently considered a better choice.^[@pby007C121]^ Furthermore, NF-kB activation has been linked to sensitization to chemo- or radiation therapies, with a strong potential to serve as a biomarker.^[@pby007C121]^ Thus, clinical trials are currently investigating NF-kB activation as a biomarker in response to radio- and chemotherapies in patients with rectal- (NCT00280761) and gastric carcinomas (NCT01905969).

Immune checkpoint inhibitors {#pby007s12}
============================

Recent exciting advancements in cancer treatment have been achieved in the field of immunotherapy. Vital fundamental discoveries over the last few decades have shown that the immune cells play a critical role in maintaining an equilibrium between immune recognition and tumor development, with the dual capacity of promoting and suppressing tumor growth.^[@pby007C122]^ It is well accepted that tumor cells derive from genetic instability, uncontrolled cell division, and reduced immunogenicity that allows tumors to evade the immune system.^[@pby007C123]^ These processes enable tumor cells to impair the immune system's capacity to eradicate them by immune suppressive effects or by loss of targetable antigen expression. Therefore, cancer immunotherapy involves use of naturally derived or synthetically generated components with the goal of activating the immune system to target the cancer.^[@pby007C123]^ Immune checkpoint inhibitors have demonstrated a considerably important breakthrough in the recent approval to treat solid tumor and hematologic malignancies in cancer immunotherapy.^[@pby007C124]^ The main concept of immune checkpoint targeting is to prevent receptors on the T cells and cancer cell ligands from binding to each other, hence disrupting signaling cascades that help cancer cells evade T cell-mediated cell death. Immune checkpoint inhibitors modulate interactions between tumor cells and cytotoxic T lymphocytes within the tumor environment, which are exhausted in their function.^[@pby007C124]^ Currently, two immune checkpoint proteins, cytotoxic T lymphocyte-associated 4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligand (PD-L1) have been evaluated. They have been found to positively influence cancer treatment outcomes, disease progression-free and/or overall survival, compared with chemotherapy-based treatment.^[@pby007C124],[@pby007C125]^ CTLA-4 and PD-1 are known to mediate immunological homeostasis by acting as downregulators of T cell activity after pathogen elimination. The FDA has already approved anti-CTLA-4 antibodies (i.e., 'Ipilimumab'), PD1 antibodies (i.e., 'Nivolumab' and 'Pembrolizumab') and PD-L1 antibodies (i.e., 'Atezolizumab'). Since 2011, these have demonstrated remarkable results either alone or in combination with other drugs or surgery for cancer treatment. This has been observed for many malignancies, including melanoma, Hodgkin's lymphoma, bladder, kidney, and/or lung cancer.^[@pby007C125]^ Many clinical trials involving combinations of these promising targeting agents are currently under investigation in various cancer types (liver, renal, ovarian, HNSCC, and pancreatic cancers) (refer to Table [4](#pby007TB4){ref-type="table"}). Further approaches to be applied in the field of hematological malignancies involve combining immune checkpoint inhibitors with chimeric antigen receptor T cells (CAR-T cells). In 2017, CD19-targeting CARs T cell therapy was approved by the FDA. The first one being 'Kymriah™,' which was used for ALL treatment in children. This therapy achieved complete remission in 83% of patients with B cell ALL, although 49% of them suffered from strong cytokine release adverse effects.^[@pby007C126]^ Similarly, 'Yescarta^TM^' is applicable for adult advanced lymphomas. Initial results show that 72% of patients positively responded to this therapy, with 51% even showing complete remission of cancer after a single infusion.^[@pby007C127]^ Currently, most of the available checkpoint inhibitor trials are in phase I/II clinical trial stages (Table [4](#pby007TB4){ref-type="table"}). There are a few ongoing phase III clinical trials, which are investigating checkpoint inhibitors in combination with a single agent (i.e 'Docetaxel,' 'Ipilimumab,' Cisplatin, 5-Fu, 'Cetuximab,' etc.) in SCLC and HNSCC (refer to Table [4](#pby007TB4){ref-type="table"}). A summary of currently ongoing clinical trials of individual, as well as combined immune checkpoint inhibitors (as registered in [ClinicalTrials.gov](ClinicalTrials.gov)) is provided in Table [4](#pby007TB4){ref-type="table"}. Table 4.Summary of checkpoint inhibitor clinical trials for human cancers. Data taken from <http://clinicaltrials.gov/>.DrugCombinationSponsorTumor typesSample sizePhasesRecruitment StatusClinical trial ID**Anti-PD1 antibody** **Nivolumab**TetrahydrouridineYogen SaunthararajahNon Small Cell Lung Cancer60IIRecruitingNCT02664181-National Cancer Institute (NCI)Ependymoma, Meningioma, Chordoma180IIRecruitingNCT03173950TIL infusionInge Marie SvaneMetastatic Ovarian Cancer12I/IIRecruitingNCT03287674-Hospital Moinhos de VentoProstate Cancer29IIRecruitingNCT03040791DenosumabAustralia and New Zealand Melanoma Trials GroupMetastatic Melanoma72I/IIRecruitingNCT03161756TAETeclison Ltd.Liver Cancer40IIRecruitingNCT03259867Viagenpumatucel-LHeat BiologicsNon Small Cell Lung Cancer120I/IIRecruitingNCT02439450RadiationGiuseppe GiacconeSmall Cell Lung Cancer56I/IIRecruitingNCT03325816IpilimumabBristol-Myers SquibbRecurrent or Metastatic HNSCCIIIRecruitingNCT02741570Interleukin-2University of Michigan Cancer CenterMetastatic Clear Cell Renal Cell Cancer23I/IIRecruitingNCT02989714Omaveloxolone or IpilimumabReata Pharmaceuticals, Inc.Melanoma102I/IIRecruitingNCT02259231 **Pembrolizumab**Gemcitabine or CisplatinCedars-Sinai Medical CenterRecurrent Platinum-resistant Ovarian Cancer25IIRecruitingNCT02608684IdelalisibZhonglin HaoNon Small Cell Lung Cancer40IRecruitingNCT03257722DocetaxelMedical University of ViennaRecurrent or Metastatic Head and Neck Cancer22I/IIRecruitingNCT02718820INCB001158Incyte CorporationAdvanced/Metastatic Solid Tumors346I/IIRecruitingNCT02903914Vitamin DTranslational Genomics Research InstitutePancreatic Cancer24IIRecruitingNCT03331562B-701BioClin Therapeutics, Inc.Advanced or Metastatic Urothelial Cell Carcinoma74I/IIRecruitingNCT03123055Methotrexate/Docetaxel/CetuximabMerck Sharp & Dohme Corp.Recurrent or Metastatic Head and Neck Cancer495IIIActive, not recruitingNCT02252042Cisplati/Carboplatin/5-FU/CetuximabMerck Sharp & Dohme Corp.Recurrent or Metastatic HNSCC825IIIActive, not recruitingNCT02358031-Kindai UniversityHepatocellular Carcinoma50IINot yet recruitingNCT03337841-BiotheraAdvanced MelanomaTriple-Negative Breast Cancer95IIRecruitingNCT02981303OlaptesedNOXXON Pharma AGColorectal and Pancreatic Cancer20I/IIRecruitingNCT03168139Laser Interstitial ThermotherapyComprehensive Cancer CenterRecurrent Glioblastoma34I/IIRecruitingNCT03277638**Pembrolizumab or Nivolumab**HyperAcute®-MelanomaNewLink Genetics CorporationMetastatic Melanoma100IIUnknownNCT02054520IBI308DocetaxelInnovent Biologics (Suzhou) Co., Ltd.Squamous Cell Lung Carcinoma266IIIRecruitingNCT03150875JS001-Shanghai Junshi Bioscience Co., Ltd.Advanced or Metastatic Bladder Urothelial Carcinoma370IIRecruitingNCT03113266JS001-Shanghai Junshi Bioscience Co., Ltd.Mucosal Melanoma220IIRecruitingNCT03178123PD-1 Antibodies-University Hospital HeidelbergMelanoma40IIRecruitingNCT03171064**Anti-PD-L1 antibody** AtezolizumabRadiotherapyGustave Roussy, Cancer Campus, Grand ParisMetastatic Tumors180IIRecruitingNCT02992912GuadecitabineUniversity of Southern CaliforniaAcute Myeloid Leukemia72I/IIRecruitingNCT02935361AtezolizumabImmune DesignSarcoma88IIActive, not recruitingNCT02609984 AvelumabCMB305Clinique Neuro-OutaouaisGlioblastoma Multiforme of Brain30IIRecruitingNCT03047473**Blocking interaction of PD1 and PDL1** DurvalumabTremelimumabSamsung Medical CenterInoperable Esophageal Cancer40IIRecruitingNCT03377400 PDR001-Novartis PharmaceuticalsAdvanced Malignancies318I/IIRecruitingNCT02404441**Anti-CTLA-4 antibody** IpilimumabNivolumabOlivia Newton-John Cancer Research InstituteGastrointestinal Cancer and Neuroendocrine Tumors60IIRecruitingNCT02923934 OlaparibCediranibNational Cancer Institute (NCI)Advanced Solid Tumors421I/IIRecruitingNCT02484404**CDK4/6 inhibitor** TrilaciclibAtezolizumabG1 Therapeutics, Inc.Small Cell Lung Cancer105IIActive, not recruitingNCT03041311**Others** Enfortumab vedotinAstellas Pharma Global Development, Inc.Advanced or Metastatic Urothelial Bladder Cancer120IIRecruitingNCT03219333 PV-10DacarbazineProvectus Biopharmaceuticals, Inc.Advanced Cutaneous Melanoma225IIIRecruitingNCT02288897 Anti-OX40 Antibody PF-04 518 600AxitinibUniversity of Southern CaliforniaMetastatic Kidney Cancer104IIRecruitingNCT03092856

Concluding remarks {#pby007s13}
==================

The way to reach the ultimate goal of precision treatment of cancer, that is the delivery of effective drugs to each individual patient, based on their characterized molecular profiles requires a considerable amount of basic research to understand the fundamentals of cancer heterogeneity. Cancer is an evolutionary complex, dynamic, and genetically heterogeneous disease, with multiple contributing factors and cellular components involved in its initiation, progression, and metastasis. This immense complexity, together with increasing resistance of tumors against currently implemented therapeutic interventions in clinical settings, requires a thorough understanding of cancer evolution at the cellular, genomic, transcriptomic, epigenetic, and proteomic levels.

In addition to conventional tools used to study cancer heterogeneity in bulk tissues, the recent development and constant optimization of more sophisticated sequencing tools at the single-cell level will continue to advance our insight and knowledge into tumor evolutionary origins, unique microenvironments, as well as metastasis. Studying intra-tumor heterogeneity and the spatial orientation of sub-clones within the primary tumor, via novel spatial transcriptomic methods together with simultaneous multiple 'omic'-sequencing, will promote specific drug targeting of individual tumor sub-clones in the near future. Examining the nature of stem-like tumor cells and the transcriptomic mechanisms required to give rise to new tumor populations, will give clarity to the origin of various metastatic disease states. Targeting these stem-like cells could hamper the spread of cancer throughout the body. Being able to longitudinally isolate and sample CTCs will permit non-invasive diagnosis and monitoring, hence enabling highly personalized treatment. Treatment approaches can be constantly modified upon tracking the response and evolution of CTCs throughout the treatment. Finally, treatment resistance can be prevented through more accurate modeling of tumor resistance development to current drugs or radiotherapy. Much work still remains to make these goals a reality, but as single-cell sequencing methods continue to become cheaper, capable of achieving higher coverage, enabling multi-omic analyses, have higher fidelity and the ability to process a greater number of cells at faster rates, there is no doubt that these goals are attainable. Thus, we are coming closer to a promising future with the enhanced ability to generate new personalized therapeutic strategies in our constant fight against cancer.
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